CD30 - Wikipedia
CD30 is the target of the FDA approved therapeutic brentuximab vedotin (Adcetris). It is approved for use in: Hodgkin lymphoma (HL) (brentuximab vedotin) after failure of autologous stem cell …
Pathology Outlines - CD30
CD30, also known as BerH2, Ki1 or TNFRSF8, is a transmembrane glycoprotein receptor that belongs to the tumor necrosis factor receptor (TNFR) and was first identified in Hodgkin …
CD30 是I型跨膜蛋白,相对分子质量为120×103 ;其编码基因位于染色体1p36 ,有2种mRNA 转录本,分别为3.4 和2.3 kb 。 人类CD30分子共有595 个氨基酸残基,包括细胞内域(188个氨基酸)、 …
CD30靶点面面观：ADC一炮而红 双抗尚无硕果 CART研发火热...
2021年4月20日 · cd30是肿瘤坏死因子（tnf）受体超家族成员之一，可通过激活不同的信号通路促进细胞增殖或凋亡，于1982年在用于霍奇金淋巴瘤（hl）细胞系的单克隆 ...
Understanding CD30 biology and therapeutic targeting: a ... - Nature
2017年9月8日 · The variable expression of CD30 on both normal and malignant lymphoid cells has focused research efforts on understanding the pathogenesis of CD30 upregulation, its …
CD30: expression and function in health and disease - PubMed
CD30 was originally described as a marker of Hodgkin's and Reed-Sternberg cells in Hodgkin's lymphoma. Cloning and characterization of cDNAs encoding CD30 and its ligand (CD30L) …
【淋巴瘤大讲堂】ADC：打入癌细胞内部杀敌的“魔法子弹”|CD30
2022年12月7日 · 1、什么是cd30？ CD30于1982年被发现，是一种分布在T细胞、B细胞等免疫细胞以及多种淋巴瘤细胞膜表面的“跨膜糖蛋白”。 “跨膜糖蛋白”，顾名思义就是贯穿细胞膜两端 …
The Polyvalent Role of CD30 for Cancer Diagnosis and Treatment
CD30, also known as TNFRSF8 (tumor necrosis factor receptor superfamily member 8), is a protein receptor that is heavily glycosylated inside the Golgi apparatus, as well as a tumor …
CD30 + lymphoproliferative disorders - PubMed Central (PMC)
CD30 antigen, originally identified as a cell surface marker of the malignant Hodgkin and Reed-Sternberg (HRS) cells in Hodgkin’s lymphoma by the use of the Ki-1 monoclonal antibody, is a …
CD30: from basic research to cancer therapy - PMC - PubMed …
Cluster determinant 30 (CD30) has been recognized since the 1980s by a monoclonal antibody (Ki-1) as an epitope of a membrane protein highly expressed on Reed–Sternberg and …